Prognostic Stage IV Breast Cancer AJCC v8 Withdrawn Phase 1 / 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0109667 (Prognostic Stage IV Breast Cancer AJCC v8)Withdrawn1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04418219Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast CancerTreatment